Overview

Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.
Phase:
Phase 2
Details
Lead Sponsor:
ICON Bioscience Inc